nach oben

Erschienen in:

01.04.2021 | News item

Use of Eylea pre-filled syringe increases risk of ocular hypertension

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Use of the aflibercept (Eylea) pre-filled syringe increases the risk of increased intraocular pressure (ocular hypertension), advises Bayer in a Direct Healthcare Professional Communication, in agreement with the European Medicines Agency and the Health Products Regulatory Authority (HPRA) in Ireland, which was published by the HPRA. …

HPRA. EYLEA 40 mg/mL (aflibercept solution for intravitreal injection) - Important Safety Information from Bayer Ltd as approved by the HPRA Internet Document : 16 Apr 2021. Available from: URL: https://www.hpra.ie/homepage/medicines/safety-notices/item?t=/eylea-40-mg-ml-(aflibercept-solution-for-intravitreal-injection)---important-safety-information-from-bayer-ltd-as-approved-by-the-hpra&id=236c0f26-9782-6eee-9b55-ff00008c97d0

Titel: Use of Eylea pre-filled syringe increases risk of ocular hypertension
Publikationsdatum: 01.04.2021
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-94461-z

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Use of Eylea pre-filled syringe increases risk of ocular hypertension

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Adalimumab/Apremilast

Dasatinib

Crizotinib/osimertinib

Nitric-oxide

Acetazolamide

Multiple drugs